Table 1.
iNKT and NK cell-mediated immunotherapy.
| Target | Modalities | Cancer | Phase | Mechanism | Reference or Clinical Trial Number |
|---|---|---|---|---|---|
| iNKT | α-GalCer-pulsed dendritic cells or antigen presenting cells | myeloma, lung | I | Activation of iNKT and NK cells | [60,61] |
| Artificial adjuvant vector cell | AML | I | Both NK and CTL were generated DC maturation in situ | [66] | |
| Ex vivo expanded iNKT cells | HNSCC, lung, melanoma | I | Direct cytotoxicity by expanded iNKT cells | [67,68,69] | |
| CAR-NKT | Neuroblastoma | I | NKT-mediated cytotoxicity against GD2+ cancer cells | [70] | |
| NK | Ex vivo expanded NK cells | AML | I | Direct cytotoxicity by expanded iNKT cells | [71] |
| iPSC-derived NK cells | AML, B-cell lymphoma, multiple myeloma | I | NK cells are regenerated from a clonal iPSC master cell line. | NCT04023071, NCT04551885, NCT04614636 | |
| CAR-NK | AML, non-Hodgkin lymphoma, CLL, BCL | I | Direct cytotoxicity by anti-CD19/CD33 CAR expressing NK cells | [72,73,74] | |
| NK cell engager | Leukemia, lymphoma | I/II | Binding CD16 on NK cells and CD30 on leukemia or lymphoma | NCT03192202 | |
| Immune checkpoint blockade | Ovarian carcinoma, squamous cervical carcinoma, END | II | Block the binding between CD94/NKG2A and HLA-E | [75] |
iNKT: invariant natural killer T cells, NK: natural killer cells, AML: acute myeloid leukemia, HNSCC: head and neck squamous cell cancer, Ab: antibody, iPSC: induced pluripotent stem cells, CAR: chimeric antigen receptor, BCL: B-cell lymphoma, CLL: chronic lymphocyte leukemia, END: epithelial endometrial carcinoma.